News | Magnetic Resonance Imaging (MRI) | October 18, 2018

Siemens Healthineers Debuts RT Pro Edition for Magnetom Sola

New 1.5T MRI scanner has intuitive, dedicated RT workflows and enables consistent scanning in treatment position

The Magnetom RT Pro edition for Magnetom Sola has an all-new magnet as well as a system architecture designed for extremely high performance and long-term stability.

At the 60th annual meeting of the American Society for Radiation Oncology (ASTRO), Oct. 21-24 at the Henry B. Gonzalez Convention Center in San Antonio, Siemens Healthineers unveiled the Magnetom RT Pro edition for Magnetom Sola – a version of the company’s new 1.5 Tesla (1.5T) magnetic resonance imaging (MRI) scanner that is designed for assistance in radiation therapy (RT) treatment planning. In addition to BioMatrix technology, which addresses patients’ anatomical and physiological differences to overcome unwanted exam variability, the new scanner includes hardware and software that supports optimal treatment planning.

The Magnetom RT Pro edition for Magnetom Sola has an all-new magnet as well as a system architecture designed for extremely high performance and long-term stability. The RT Dot engine predefines RT strategies, automatically corrects for image distortion to improve spatial integrity, and automatically reconstructs axial images to enable direct processing of all data in RT planning software. It also offers an interface with RT positioning lasers to support accurate patient positioning.

The scanner’s new, dedicated RT post-planning software, RT Image Suite, permits the calculation of synthetic computed tomography (CT) images derived from MR images. These synthetic CT images provide essential information for patients with brain and prostate tumors that typically had been acquired with CT, eliminating the need for patients to lie on the treatment bed for two separate imaging sessions. RT Image Suite is also new to the RT Pro Edition for Magnetom Vida, the 3T scanner for assistance in RT planning that debuted at ASTRO 2017.

Additionally, Resolve software reduces distortions associated with MR diffusion imaging by a factor of three, enabling the use of these images in the dose planning process for the linear accelerator.

“With the introduction of the Magnetom RT Pro edition for Magnetom Sola, Siemens Healthineers once again raises the bar in the development of MRI scanners for assistance in radiation therapy planning, with features such as RT Image Suite that expand precision medicine and improve the overall patient experience,” said Hanno Dotzel, Vice President of Radiation Oncology at Siemens Healthineers North America.

For more information: www.usa.healthcare.siemens.com

Related Content

These MRI scans show diffuse white matter abnormality (DWMA). The top three panels display raw MRI images from very preterm infants born at 27 weeks (left), 26 weeks (center) and 31 weeks (right) gestation.

These MRI scans show diffuse white matter abnormality (DWMA). The top three panels display raw MRI images from very preterm infants born at 27 weeks (left), 26 weeks (center) and 31 weeks (right) gestation. Higher signal intensity can be seen in the central white matter, particularly for the 31-week gestation infant. The bottom panels display the corresponding slices with objectively segmented DWMA in yellow. The 27-week infant (left) was diagnosed with mild DWMA, the 26-week infant (center) was diagnosed with moderate DWMA, and the 31-week infant had severe DWMA. Image courtesy of Cincinnati Children's and Nature Scientific Reports

News | Magnetic Resonance Imaging (MRI) | October 01, 2020
October 1, 2020 — As many as 70% of very premature infants (born earlier than 32 weeks gestation) show signs of white
he Centers for Medicare and Medicaid Services (CMS) published the “Specialty Care Models to Improve Quality of Care and Reduce Expenditures (CMS-5527)” final rule.

Getty Images

News | Radiation Oncology | September 29, 2020
September 29, 2020 — On Sept.
Important milestone demonstrates the unrivalled experience, technological innovation and global market leadership of IBA and its clinical partners
News | Proton Therapy | September 25, 2020
September 25, 2020 — IBA (Ion Beam Applications SA) announced that more than 100,000 patients have now been treated w
The cartilage in this MRI scan of a knee is colorized to show greater contrast between shades of gray.

The cartilage in this MRI scan of a knee is colorized to show greater contrast between shades of gray. Image courtesy of Kundu et al. (2020) PNAS

News | Artificial Intelligence | September 22, 2020
September 22, 2020 — Researchers at the University of Pitts...
Final rule includes mandatory participation for nearly 1,000 practices and does not allow sufficient time for transition

Getty Images

News | Radiation Oncology | September 21, 2020
September 21, 2020 — In response to the September 18 ...
According to a new report published by P&S Intelligence, the global radiotherapy market is expected to expand from $7.2M in 2019 to $17M by 2030.

Image courtesy of Accuray

Feature | Radiation Therapy | September 21, 2020 | By Melinda Taschetta-Millane
According to a...
A new report, Magnetic Resonance Imaging Equipment Market Size, Share & Industry Analysis, conducted by Fortune Business Insights, states that the magnetic resonance imaging (MRI) equipment market reached $7.24 billion in 2019 and is projected to reach $11.36 billion by 2027

Image courtesy of Siemens Healthineers

Feature | Magnetic Resonance Imaging (MRI) | September 21, 2020 | By Melinda Taschetta-Millane
A new report,...
Figure 1. Doppler flows in subpleural consolidation shows smoothly dilated branching arteries

Figure 1. Doppler flows in subpleural consolidation shows smoothly dilated branching arteries 

Feature | Radiology Imaging | September 17, 2020 | By Robert Bard, M.D. PC, DABR, FASLM
COVID-19 is routinely studied using...
Varian Drives Next Evolution of Proton Treatment Planning with Eclipse v16.1
News | Treatment Planning | September 15, 2020
September 15, 2020 — Varian announced it has received FDA 510(k) clearance for its Eclipse v16.1 treatment planning s